Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX's lead programs are peptide-based therapeutics delivered via a proprietary long-acting Precision Endocrine Peptide (PEP™) platform, i.e., Peptide Therapeutics.
|
$1.52B |
$33.77
+1.66%
|
|
VIR
Vir Biotechnology, Inc.
PRO-XTEN masking platform represents a drug delivery platform intended to improve safety and therapeutic index.
|
$1.50B |
$10.76
+4.11%
|
|
ATRC
AtriCure, Inc.
AtriCure directly manufactures surgical equipment and devices used in operating rooms and minimally invasive cardiac procedures.
|
$1.48B |
$29.73
+2.94%
|
|
PVLA
Palvella Therapeutics, Inc.
Palvella Therapeutics concentrates on rare genetic skin diseases and markets a proprietary topical rapamycin platform (QTORIN), indicating a core focus on rare disease biotech development.
|
$1.47B |
$131.44
-0.89%
|
|
NVCR
NovoCure Limited
NovoCure's TTFields cancer therapy device (Optune) is a medical device sold to treat cancer, fitting the Medical Devices & Biometrics category.
|
$1.44B |
$12.84
+1.74%
|
|
NVAX
Novavax, Inc.
Novavax develops, manufactures, and commercializes vaccines (e.g., Nuvaxovid), placing it squarely in the vaccines product category.
|
$1.44B |
$8.82
+2.14%
|
|
ARDT
Ardent Health Partners, LLC
Ardent operates hospitals delivering acute inpatient and related hospital services.
|
$1.42B |
$9.89
+4.77%
|
|
AVAH
Aveanna Healthcare Holdings Inc.
AVAH directly provides Home Health and Hospice services to patients in home settings.
|
$1.41B |
$6.76
+0.75%
|
|
VRDN
Viridian Therapeutics, Inc.
Lead programs Veligrotug and VRDN-003 are monoclonal antibodies targeting IGF-1R, i.e., Monoclonal Antibody Therapeutics.
|
$1.41B |
$14.80
+0.99%
|
|
PGEN
Precigen, Inc.
Direct platform and lead asset are gene therapy products, making Biotech - Gene Therapy a core tag.
|
$1.41B |
$3.96
+0.38%
|
|
PRCT
PROCEPT BioRobotics Corporation
PROCEPT's Aquablation robotic systems are surgical equipment sold for urology procedures.
|
$1.40B |
$25.14
+2.51%
|
|
TNDM
Tandem Diabetes Care, Inc.
Tandem Diabetes Care manufactures insulin pumps (medical devices) and biometric sensing data integration, a core medical device product line.
|
$1.40B |
$20.61
+2.59%
|
|
BFLY
Butterfly Network, Inc.
Core ultrasound imaging hardware and point-of-care devices (POCUS) produced by Butterfly.
|
$1.38B |
$5.46
+3.12%
|
|
IMTX
Immatics N.V.
Core product platform: TCR-engineered cell therapies (ACT) for solid tumors.
|
$1.36B |
$11.18
+2.81%
|
|
MAZE
Maze Therapeutics, Inc.
Maze develops small molecule therapeutics, including MZE829 and MZE782, which are oral small molecule treatments for renal/cardiovascular/metabolic diseases.
|
$1.35B |
$28.06
+4.43%
|
|
KMTS
Kestra Medical Technologies, Ltd.
Core product is Cardiology devices: wearable defibrillator (ASSURE WCD) and related cardiac therapy platform.
|
$1.33B |
$22.83
+11.86%
|
|
ASTH
Astrana Health, Inc.
Astrana operates outpatient clinics and ambulatory surgical centers, i.e., care delivery services.
|
$1.32B |
$23.86
+6.21%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Directly focused on oncology therapeutics; Bicara's lead candidate is an antibody-based cancer therapy.
|
$1.32B |
$23.98
+0.21%
|
|
NNE
Nano Nuclear Energy Inc
Company engages in laboratory testing/advisory services related to nuclear tech development and regulatory readiness.
|
$1.30B |
$25.89
+5.46%
|
|
AHG
Akso Health Group
Sale of medical devices and biometrics hardware.
|
$1.30B |
$2.33
-0.85%
|
|
GLUE
Monte Rosa Therapeutics, Inc.
GLUE develops oral small-molecule molecular glue degraders (MGDs) as its core therapeutic modality.
|
$1.29B |
$19.80
+5.91%
|
|
INBX
Inhibrx Biosciences, Inc.
Clinical-stage oncology biotech with DR5 and OX40 antibody programs.
|
$1.28B |
$88.42
+6.39%
|
|
ALNT
Allient Inc.
Medical Device Components align with Allient’s product capabilities used in medical device applications.
|
$1.26B |
$74.37
+5.65%
|
|
WVE
Wave Life Sciences Ltd.
Wave Life Sciences' core products are stereopure oligonucleotides and oligonucleotide therapeutics (antisense/siRNA/editing AIMers) used as RNA medicines.
|
$1.25B |
$7.49
+2.32%
|
|
CRVS
Corvus Pharmaceuticals, Inc.
Lead pipeline includes oncology-focused therapies (soquelitinib) with activity in T-cell lymphomas, aligning with Oncology-focused biotech development.
|
$1.25B |
$16.72
+11.17%
|
|
STAA
STAAR Surgical Company
STAAR directly manufactures ophthalmic medical devices, primarily implantable lenses (EVO ICL) used for vision correction.
|
$1.25B |
$25.10
+1.95%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Lead asset is an ophthalmic drug (DURAVYU) targeting wet AMD and DME.
|
$1.24B |
$14.96
+1.01%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
Company focuses on oncology therapeutics, positioning it within Biotech - Oncology.
|
$1.22B |
$29.73
+0.41%
|
|
CNMD
CONMED Corporation
CNMD's product portfolio consists of medical devices and equipment broadly, aligning with the Medical Devices & Biometrics category.
|
$1.21B |
$39.09
+3.11%
|
Showing page 13 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
